Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. - PE Ratioverified

LCTX

Price:

$1.21

Market Cap:

$301.65M

Lineage Cell Therapeutics, Inc. (LCTX) operates as a biotechnology firm in the clinical trial phase, dedicated to pioneering innovative cell-based treatments for various degenerative conditions across the United States and globally. The company's pipeline features several key therapeutic candidates: OpRegen, a replacement therapy utilizing retinal pigment epithelium cells, is currently undergoing Phase I/IIa clinical trials to address dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, is being evaluated in Phase I/IIa multicenter clinical studies for individuals suffering from acute spinal cord injuries. VAC2, an allogeneic cancer immunotherapy employing ...[Read more]

Industry

Biotechnology

IPO Date

1992-03-05

Stock Exchange

AMEX

Ticker

LCTX

The PE Ratio as of June 2026 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is -4.17

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.17. This represents a change of -117.72% compared to the average of 23.53 of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical PE Ratio (quarterly & annually)

How has LCTX PE Ratio performed in the past?

The mean historical PE Ratio of Lineage Cell Therapeutics, Inc. over the last ten years is -6.61. The current -4.17 PE Ratio has changed 6.21% with respect to the historical average. Over the past ten years (40 quarters), LCTX's PE Ratio was at its highest in in the December 2025 quarter at 119.29. The PE Ratio was at its lowest in in the March 2021 quarter at -66.01.

Quarterly (TTM)
Annual

Average

-6.61

Median

-8.44

Minimum

-12.65

Maximum

10.31

Lineage Cell Therapeutics, Inc. (LCTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 333.07%

Maximum Annual PE Ratio = 10.31

Minimum Annual Increase = -248.43%

Minimum Annual PE Ratio = -12.65

Quarterly (TTM)
Annual
YearPE RatioChange
2025-5.9610.38%
2024-5.40-40.51%
2023-9.0816.45%
2022-7.80-17.22%
2021-9.42-25.04%
2020-12.5714.84%
2019-10.95333.07%
2018-2.53-80.01%
2017-12.65-222.62%
201610.31-248.43%

Lineage Cell Therapeutics, Inc. (LCTX) Average PE Ratio

How has LCTX PE Ratio performed in the past?

The current PE Ratio of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.82

5-year avg

-7.53

10-year avg

-6.61

Lineage Cell Therapeutics, Inc. (LCTX) PE Ratio vs. Peers

How is LCTX’s PE Ratio compared to its peers?

Lineage Cell Therapeutics, Inc.’s PE Ratio is greater than Neurogene Inc. (-6.27), greater than Ocugen, Inc. (-5.32), greater than Benitec Biopharma Inc. (-10.95), less than ADC Therapeutics S.A. (-1.04), less than Autolus Therapeutics plc (-1.39), less than Fulcrum Therapeutics, Inc. (-3.22), less than PureTech Health plc (-0.60), greater than Galectin Therapeutics Inc. (-6.94), less than Omeros Corporation (7.91), greater than RAPT Therapeutics, Inc. (-14.81),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Lineage Cell Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the highest PE Ratio for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 3-year average PE Ratio for Lineage Cell Therapeutics, Inc. (LCTX)?

What is the 5-year average PE Ratio for Lineage Cell Therapeutics, Inc. (LCTX)?

How does the current PE Ratio for Lineage Cell Therapeutics, Inc. (LCTX) compare to its historical average?